SOMA 250 CIV
Generic Name and Formulations:
Carisoprodol 250mg; tabs.
Mylan Specialty L.P.
Indications for SOMA 250:
Relief of acute, painful musculoskeletal conditions.
≥16yrs: 250mg–350mg 3 times daily and at bedtime. Max 2–3 weeks.
<16yrs: not recommended.
Renal or hepatic dysfunction. Drug abuse. Pregnancy (Cat.C). Nursing mothers.
Sedative effects potentiated by alcohol, other CNS depressants. May be potentiated by CYP2C19 inhibitors (eg, omeprazole, fluvoxamine). May be antagonized by CYP2C19 inducers (eg, rifampin, St. John's Wort).
Muscle relaxant (central).
Dizziness, drowsiness, headache, GI upset, rash, tachycardia, orthostatic hypotension; rare idiosyncratic reactions (see literature).
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders